Professor H Rogier van Doorn
Contact information
Podcast interview
Antimicrobial resistance in Vietnam
OUCRU Hanoi runs a research program on antimicrobial resistance, focusing on the widespread resistance due to antibiotic overuse. Causing over 1.2 million deaths annually, AMR surpasses many major diseases. Our work includes community intervention trials, hospital stewardship programmes and extensive surveillance projects, aiming to inform and implement effective antibiotic use and policies globally.
H Rogier van Doorn
Professor of Infectious Diseases
- Clinical Microbiologist
OUCRU Ha Noi
Rogier is a Clinical Microbiologist from the Netherlands who has worked at OUCRU since the end of 2007. In his role as head of the virology lab for the Southeast Asian Infectious Disease Clinical Research Network he has led analysis of several diagnostic and intervention studies on human influenza, developed diagnostic lab capacity in local hospitals and BSL3/SAPO4 facility at OUCRU. As head of the Emerging Infections group he has worked on diagnostics and clinical research of emerging infections, led a multifaceted research program on Hand, Foot and Mouth Disease, and projects on pathogen discovery.
Currently, Rogier leads the OUCRU Ha Noi unit with research focus on antimicrobial resistance and influenza and other respiratory infections.
Recent publications
A case series of Candidozyma auris in Viet Nam.
Journal article
Pham VP. et al, (2026), BMC Infect Dis, 26
Prospective characterisation of drug-resistant bloodstream infections in Africa and Asia (ACORN2): a surveillance network assessment.
Journal article
Hopkins J. et al, (2026), Lancet Microbe, 7
Factors associated with positive blood cultures in children in nine African and Asian countries: the ACORN2 surveillance network.
Journal article
Ardura-Garcia C. et al, (2025), BMJ Glob Health, 10
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group ., (2025), Lancet Infect Dis, 25, 1000 - 1010
